Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11984MR)

This product GTTS-WQ11984MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ11984MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13561MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ7524MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ10536MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ10448MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ445MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ11463MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ12347MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ8957MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW